# Cyclooxygenase (COX) Inhibitors

## Prototype

- `Aspirin` (acetylsalicylic acid)

## Mechanism of Action

- Normally, platelets contain **COX-1 enzyme** that converts **arachidonic acid → prostaglandin G₂/H₂ → thromboxane A₂ (TXA₂)**.
- **Aspirin irreversibly acetylates** and inhibits **COX-1** enzyme in platelets.
- This inhibition blocks TXA₂ synthesis → **↓ platelet aggregation** and **↓ vasoconstriction**.
- Since platelets are **anucleate** (no nucleus), they **cannot resynthesize COX-1**. Thus, the effect lasts for the **entire platelet lifespan (~7–10 days)**.

![COX inhibitors MOA](/pharmacology/cvs/anti-platelets/cox-inhibitors.png)

## Pharmacokinetics

| Feature        | Details                                    |
| :------------- | :----------------------------------------- |
| **Route**      | Oral (common), IV or rectal (rare)         |
| **Onset**      | Within minutes after ingestion             |
| **Duration**   | 7–10 days (until new platelets are formed) |
| **Metabolism** | Hepatic; metabolites excreted via kidneys  |

## Dose (for antiplatelet effect)

- **Low dose:** 75–150 mg/day (usually 81 or 100 mg daily)
- **Mechanism at low dose:** Selective inhibition of **platelet COX-1** without affecting endothelial COX-2 (so prostacyclin, PGI₂, remains intact).

_(Higher doses inhibit prostacyclin, losing selectivity and potentially counteracting benefits.)_

## Adverse Effects

| System               | Adverse effect                       | Explanation                                        |
| :------------------- | :----------------------------------- | :------------------------------------------------- |
| **Gastrointestinal** | Gastritis, ulceration, bleeding      | Due to ↓ prostaglandins (↓ mucosal protection)     |
| **Hematologic**      | Prolonged bleeding time              | Platelet inhibition                                |
| **Allergic**         | Bronchospasm, urticaria              | Especially in aspirin-sensitive asthma             |
| **Renal**            | ↓ renal perfusion (rare at low dose) | Prostaglandin inhibition                           |
| **Reye’s syndrome**  | Children with viral infections       | Hepatic encephalopathy (hence avoid in \<12 years) |

## Contraindications

- Active peptic ulcer or GI bleed
- Hemorrhagic disorders (e.g. hemophilia)
- Aspirin hypersensitivity
- Children with viral infections (risk of Reye’s)
- Severe hepatic or renal impairment

## Therapeutic Uses

| Indication                                             | Rationale                                                |
| :----------------------------------------------------- | :------------------------------------------------------- |
| **Myocardial infarction (MI) prophylaxis and post-MI** | Prevents platelet aggregation at atherosclerotic plaques |
| **Unstable angina / acute coronary syndrome (ACS)**    | Given immediately (chewed for rapid absorption)          |
| **Post-angioplasty / CABG**                            | To prevent thrombus formation                            |
| **Cerebrovascular disease (TIA, stroke)**              | Secondary prevention of ischemic stroke                  |
| **Peripheral arterial disease (PAD)**                  | To reduce vascular events                                |

## Drug Interactions

| With                                        | Result                                                                       |
| :------------------------------------------ | :--------------------------------------------------------------------------- |
| **NSAIDs (e.g. ibuprofen)**                 | May antagonize aspirin’s irreversible COX inhibition if taken simultaneously |
| **Anticoagulants (e.g. warfarin, heparin)** | ↑ bleeding risk                                                              |
| **Corticosteroids**                         | ↑ GI bleeding risk                                                           |
| **Alcohol**                                 | ↑ mucosal damage, bleeding risk                                              |

## Key Points Summary

|                     |                                               |
| :------------------ | :-------------------------------------------- |
| **Mechanism**       | Irreversible COX-1 inhibition → ↓ TXA₂        |
| **Effect duration** | Until new platelets form (~7–10 days)         |
| **Dose**            | 75–150 mg/day for antiplatelet                |
| **Main use**        | Secondary prevention of MI and stroke         |
| **Major AE**        | GI bleeding                                   |
| **Antidote**        | None; platelet transfusion if bleeding severe |
